HK1171228A1 - Mglu2 agonists mglu2 - Google Patents

Mglu2 agonists mglu2

Info

Publication number
HK1171228A1
HK1171228A1 HK12112042.9A HK12112042A HK1171228A1 HK 1171228 A1 HK1171228 A1 HK 1171228A1 HK 12112042 A HK12112042 A HK 12112042A HK 1171228 A1 HK1171228 A1 HK 1171228A1
Authority
HK
Hong Kong
Prior art keywords
mglu2
agonists
mglu2 agonists
agonists mglu2
Prior art date
Application number
HK12112042.9A
Other languages
English (en)
Inventor
James Allen Monn
Lourdes Prieto
Martinez Lorena Taboada
Salgado Carlos Montero
Bruce William Shaw
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42026702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1171228(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1171228A1 publication Critical patent/HK1171228A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK12112042.9A 2009-12-21 2012-11-23 Mglu2 agonists mglu2 HK1171228A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382290 2009-12-21
US30523910P 2010-02-17 2010-02-17
PCT/US2010/060371 WO2011084437A1 (en) 2009-12-21 2010-12-15 Mglu2 agonists

Publications (1)

Publication Number Publication Date
HK1171228A1 true HK1171228A1 (en) 2013-03-22

Family

ID=42026702

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12112042.9A HK1171228A1 (en) 2009-12-21 2012-11-23 Mglu2 agonists mglu2

Country Status (35)

Country Link
US (1) US8318184B2 (el)
EP (1) EP2516406B1 (el)
JP (1) JP5779190B2 (el)
KR (1) KR101395356B1 (el)
CN (1) CN102695701B (el)
AR (1) AR079343A1 (el)
AU (1) AU2010340039B2 (el)
BR (1) BR112012017188B1 (el)
CA (1) CA2784667C (el)
CR (1) CR20120322A (el)
CY (1) CY1114880T1 (el)
DK (1) DK2516406T3 (el)
DO (1) DOP2012000173A (el)
EA (1) EA020229B1 (el)
EC (1) ECSP12011989A (el)
ES (1) ES2435651T3 (el)
HK (1) HK1171228A1 (el)
HN (1) HN2012001160A (el)
HR (1) HRP20131052T1 (el)
IL (1) IL220011A (el)
JO (1) JO2978B1 (el)
MA (1) MA33824B1 (el)
MX (1) MX2012007332A (el)
MY (1) MY160618A (el)
NZ (1) NZ600305A (el)
PE (1) PE20121688A1 (el)
PL (1) PL2516406T3 (el)
PT (1) PT2516406E (el)
RS (1) RS53063B (el)
SG (1) SG181836A1 (el)
SI (1) SI2516406T1 (el)
TN (1) TN2012000281A1 (el)
TW (1) TWI477490B (el)
UA (1) UA107684C2 (el)
WO (1) WO2011084437A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2540728B1 (en) 2010-02-17 2019-04-10 Takeda Pharmaceutical Company Limited Heterocyclic compound
AR083845A1 (es) * 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3
CN103209954B (zh) * 2010-11-18 2015-09-02 伊莱利利公司 作为mGluR2/3拮抗剂的4-取代的-3-苄氧基-双环[3.1.0]己烷化合物
RS54888B1 (sr) 2011-06-17 2016-10-31 Lilly Co Eli Derivati biciklo(3.1.0)heksan-2,6-dikarboksilne kiseline kao agonisti mglu2 receptora
AR089718A1 (es) * 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
KR20220038826A (ko) 2014-01-21 2022-03-29 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
LT3431106T (lt) 2014-01-21 2021-02-10 Janssen Pharmaceutica Nv Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
EP3277270B1 (en) 2015-04-01 2021-10-27 Akebia Therapeutics, Inc. Compositions and methods for treating anemia

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576323A (en) * 1993-12-03 1996-11-19 Eli Lilly And Company Excitatory amino acid receptor antagonists
GB9605429D0 (en) 1995-11-16 1996-05-15 Lilly Co Eli Excitatory amino acid receptor antagonists
US5688826A (en) 1995-11-16 1997-11-18 Eli Lilly And Company Excitatory amino acid derivatives
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
EP1351925A1 (en) * 2001-01-11 2003-10-15 Eli Lilly And Company Prodrugs of excitatory amino acids
IL156364A0 (en) * 2001-01-11 2004-01-04 Lilly Co Eli Prodrugs of excitatory amino acids
WO2002068380A1 (en) * 2001-02-22 2002-09-06 Eli Lilly And Company Synthetic excitatory amino acids
US7371872B2 (en) 2002-06-11 2008-05-13 Eli Lilly And Company Prodrugs of excitatory amino acids
US7381746B2 (en) * 2003-06-26 2008-06-03 Taisho Pharmaceutical Co., Ltd. 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative
AR083845A1 (es) * 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3
CN103209954B (zh) * 2010-11-18 2015-09-02 伊莱利利公司 作为mGluR2/3拮抗剂的4-取代的-3-苄氧基-双环[3.1.0]己烷化合物

Also Published As

Publication number Publication date
TWI477490B (zh) 2015-03-21
ECSP12011989A (es) 2012-07-31
PT2516406E (pt) 2013-10-10
AU2010340039B2 (en) 2014-03-20
CN102695701B (zh) 2014-10-01
BR112012017188A2 (pt) 2016-03-22
MX2012007332A (es) 2012-07-20
BR112012017188A8 (pt) 2016-10-04
JP2013514974A (ja) 2013-05-02
HRP20131052T1 (hr) 2013-12-06
DK2516406T3 (da) 2013-10-14
EP2516406B1 (en) 2013-09-18
ES2435651T3 (es) 2013-12-20
MA33824B1 (fr) 2012-12-03
JO2978B1 (en) 2016-03-15
MY160618A (en) 2017-03-15
CY1114880T1 (el) 2016-12-14
PL2516406T3 (pl) 2014-03-31
HN2012001160A (es) 2015-08-24
US20110152334A1 (en) 2011-06-23
RS53063B (en) 2014-04-30
AR079343A1 (es) 2012-01-18
CA2784667A1 (en) 2011-07-14
UA107684C2 (xx) 2015-02-10
US8318184B2 (en) 2012-11-27
KR101395356B1 (ko) 2014-05-14
TN2012000281A1 (en) 2013-12-12
JP5779190B2 (ja) 2015-09-16
NZ600305A (en) 2014-01-31
CN102695701A (zh) 2012-09-26
IL220011A (en) 2014-03-31
EA201290558A1 (ru) 2012-12-28
SG181836A1 (en) 2012-08-30
KR20120094056A (ko) 2012-08-23
CR20120322A (es) 2012-07-10
BR112012017188B1 (pt) 2021-06-22
DOP2012000173A (es) 2012-11-30
TW201144290A (en) 2011-12-16
AU2010340039A1 (en) 2012-08-09
PE20121688A1 (es) 2012-12-05
SI2516406T1 (sl) 2013-11-29
CA2784667C (en) 2014-11-18
EP2516406A1 (en) 2012-10-31
WO2011084437A1 (en) 2011-07-14
EA020229B1 (ru) 2014-09-30
IL220011A0 (en) 2012-07-31

Similar Documents

Publication Publication Date Title
GB0919432D0 (en) Use
EP2488033A4 (en) COMBINATION
IL220526A0 (en) Kokumi-imparting agent
ZA201702958B (en) Novel npr-b agonists
EP2478768A4 (en) ANTIPHYTOVIRAL AGENT
HK1171228A1 (en) Mglu2 agonists mglu2
IL220527A0 (en) Kokumi-imparting agent
EP2407165A4 (en) ANTIOXIDANTS
ZA201202416B (en) Combination
GB0922505D0 (en) Use
EP2433502A4 (en) AGENT FOR REMOVING AMERTUME
IL219786A0 (en) Combination
IL218999A0 (en) Combination
IL218797A0 (en) Combination
IL219000A0 (en) Combination
IL218846A0 (en) Combination
PL2427617T3 (pl) Okucie
IL218801A0 (en) Combination
GB0917304D0 (en) Use
GB0909625D0 (en) Monitors
GB0901585D0 (en) Service Provision
GB0907963D0 (en) Use
GB0919586D0 (en) Use
GB0912237D0 (en) Use
GB0919888D0 (en) Use